{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:21:17Z","timestamp":1783506077615,"version":"3.55.0"},"reference-count":92,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA256893"],"award-info":[{"award-number":["R01 CA256893"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA264652"],"award-info":[{"award-number":["R01 CA264652"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA157429"],"award-info":[{"award-number":["R01 CA157429"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA272483"],"award-info":[{"award-number":["R01 CA272483"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA266579"],"award-info":[{"award-number":["R01 CA266579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Enzalutamide resistance remains a key challenge in the treatment of advanced prostate cancer (PCa), as clinical efficacy is frequently hindered by acquired resistance. While reactivation of AR signaling, including AR splice variants, has been extensively studied, accumulating evidence indicates that metabolic reprogramming is a key adaptive response to sustained AR inhibition. As resistance advances, tumor cells exhibit metabolic plasticity, dynamically regulating glycolysis, mitochondrial respiration, lipid metabolism, and redox homeostasis to adapt to treatment pressure. In this context, phosphoglycerate kinase 1 (PGK1), a key glycolytic enzyme, has emerged as a potential mediator linking metabolic adaptation to therapy resistance. Beyond its ATP-generating function, PGK1 exhibits non-canonical functions, including regulation of mitochondrial metabolism, protein kinase activity, and stress-response signaling. These properties suggest that PGK1 may integrate AR-driven metabolic programs with downstream survival pathways under therapeutic pressure. Preclinical studies support a role for PGK1 in promoting glycolytic phenotypes and resistance-associated metabolic states. However, current evidence remains largely associative, and direct in vivo validation in prostate-specific models is limited. Moreover, whether PGK1 functions as a causal driver or downstream effector of resistance remains unresolved. This review summarizes current understanding of AR\u2013metabolism coupling and evaluates PGK1 as a potential metabolic-signaling node in enzalutamide resistance, highlighting key knowledge gaps and future directions for metabolic targeting in PCa.<\/jats:p>","DOI":"10.1210\/endocr\/bqag063","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:50:14Z","timestamp":1779450614000},"source":"Crossref","is-referenced-by-count":0,"title":["Metabolic plasticity and enzalutamide resistance: emerging roles of PGK1 in prostate cancer"],"prefix":"10.1210","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5134-9438","authenticated-orcid":false,"given":"Min","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky , Lexington, KY 40536 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky , Lexington, KY 40536 ,","place":["USA"]},{"name":"Markey Cancer Center, University of Kentucky , Lexington, KY 40536 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"issue":"2","key":"2026070806070559900_bqag063-B1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"1","key":"2026070806070559900_bqag063-B2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12957-025-03733-1","article-title":"Global burden of prostate cancer: age-period-cohort analysis from 1990 to 2021 and projections until 2040","volume":"23","author":"Chu","year":"2025","journal-title":"World J Surg Oncol"},{"issue":"1","key":"2026070806070559900_bqag063-B3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12957-025-03937-5","article-title":"Global, regional, and national burden and trends of prostate cancer in elderly from 1990 to 2021: results from global burden of disease 2021","volume":"23","author":"Li","year":"2025","journal-title":"World J Surg Oncol"},{"issue":"5","key":"2026070806070559900_bqag063-B4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1055-9965.EPI-22-1038","article-title":"Estimating the number of men living with metastatic prostate cancer in the United States","volume":"32","author":"Devasia","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"2026070806070559900_bqag063-B5","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3390\/molecules25102448","article-title":"Second-generation androgen receptor antagonists as hormonal therapeutics for three forms of prostate cancer","volume":"25","author":"Rajaram","year":"2020","journal-title":"Molecules"},{"issue":"7","key":"2026070806070559900_bqag063-B6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"issue":"3","key":"2026070806070559900_bqag063-B7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41391-024-00829-9","article-title":"Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials","volume":"27","author":"Shelan","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"2026070806070559900_bqag063-B8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14737140.2024.2405103","article-title":"Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment","volume":"24","author":"Miller","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026070806070559900_bqag063-B9","doi-asserted-by":"crossref","first-page":"1542811","DOI":"10.3389\/fonc.2025.1542811","article-title":"Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"issue":"4","key":"2026070806070559900_bqag063-B10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to Abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"issue":"19","key":"2026070806070559900_bqag063-B11","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.3390\/cancers14194877","article-title":"The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026070806070559900_bqag063-B12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.17161\/sjm.v2i4.24058","article-title":"Mechanisms and therapeutic strategies to overcome enzalutamide resistance in advanced prostate cancer","volume":"2","author":"Wang","year":"2025","journal-title":"Serican J Med"},{"issue":"16","key":"2026070806070559900_bqag063-B13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/cells13161396","article-title":"Impact of neuroendocrine differentiation (NED) on enzalutamide and Abiraterone efficacy in metastatic castration-resistant prostate cancer (mCRPC): a retrospective analysis","volume":"13","author":"Farinea","year":"2024","journal-title":"Cells"},{"issue":"13","key":"2026070806070559900_bqag063-B14","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.3390\/ijms26135939","article-title":"Phenotypic plasticity and androgen receptor bypass drive cross-resistance to apalutamide in castration-resistant prostate cancer cell models","volume":"26","author":"Simon","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026070806070559900_bqag063-B15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","article-title":"Metabolic reprogramming in prostate cancer","volume":"125","author":"Ahmad","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"2026070806070559900_bqag063-B16","first-page":"143","article-title":"Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer","volume":"4","author":"Chetta","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"24","key":"2026070806070559900_bqag063-B17","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1097\/CM9.0000000000003844","article-title":"Revisiting the role of metabolic reprogramming as a contributor to prostate cancer disease progression","volume":"138","author":"Ding","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"2026070806070559900_bqag063-B18","doi-asserted-by":"crossref","first-page":"580617","DOI":"10.3389\/fonc.2020.580617","article-title":"Androgen receptor signaling and metabolic and cellular plasticity during progression to castration resistant prostate cancer","volume":"10","author":"Uo","year":"2020","journal-title":"Front Oncol"},{"key":"2026070806070559900_bqag063-B19","doi-asserted-by":"crossref","first-page":"117863","DOI":"10.1016\/j.lfs.2020.117863","article-title":"Phosphoglycerate kinase 1 (PGK1) in cancer: a promising target for diagnosis and therapy","volume":"256","author":"Fu","year":"2020","journal-title":"Life Sci"},{"key":"2026070806070559900_bqag063-B20","doi-asserted-by":"crossref","first-page":"174835","DOI":"10.1016\/j.ejphar.2022.174835","article-title":"The basic functions of phosphoglycerate kinase 1 and its roles in cancer and other diseases","volume":"920","author":"Liu","year":"2022","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2026070806070559900_bqag063-B21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12964-023-01256-4","article-title":"Regulation of phosphoglycerate kinase 1 and its critical role in cancer","volume":"21","author":"Zhang","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"3","key":"2026070806070559900_bqag063-B22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5534\/wjmh.180040","article-title":"Role of androgen receptor in prostate cancer: a review","volume":"37","author":"Fujita","year":"2019","journal-title":"World J Mens Health"},{"issue":"5","key":"2026070806070559900_bqag063-B23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/cells11050898","article-title":"Androgen receptor-mediated transcription in prostate cancer","volume":"11","author":"\u00d6zturan","year":"2022","journal-title":"Cells"},{"key":"2026070806070559900_bqag063-B24","doi-asserted-by":"crossref","first-page":"924087","DOI":"10.3389\/fmed.2022.924087","article-title":"Androgen receptor signaling and spatial chromatin organization in castration-resistant prostate cancer","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026070806070559900_bqag063-B25","doi-asserted-by":"crossref","first-page":"926585","DOI":"10.3389\/fendo.2022.926585","article-title":"The role of epigenetic change in therapy-induced neuroendocrine prostate cancer lineage plasticity","volume":"13","author":"Storck","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026070806070559900_bqag063-B26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40880-019-0401-9","article-title":"Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis","volume":"39","author":"Shao","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"2026070806070559900_bqag063-B27","doi-asserted-by":"crossref","first-page":"7711151","DOI":"10.1155\/2021\/7711151","article-title":"Systematic analysis uncovers associations of PGK1 with prognosis and immunological characteristics in breast cancer","volume":"2021","author":"Li","year":"2021","journal-title":"Dis Markers"},{"issue":"5","key":"2026070806070559900_bqag063-B28","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.3390\/ijms25052630","article-title":"Integrative metabolomic analysis of Serum and selected Serum exosomal microRNA in metastatic castration-resistant prostate cancer","volume":"25","author":"Evin","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026070806070559900_bqag063-B29","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s43018-024-00820-2","article-title":"Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers","volume":"5","author":"Dong","year":"2024","journal-title":"Nat Cancer"},{"issue":"40","key":"2026070806070559900_bqag063-B30","doi-asserted-by":"crossref","first-page":"e2402741121","DOI":"10.1073\/pnas.2402741121","article-title":"Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics","volume":"121","author":"Wang","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2026070806070559900_bqag063-B31","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/s41388-021-02157-x","article-title":"SOX2 mediates metabolic reprogramming of prostate cancer cells","volume":"41","author":"de Wet","year":"2022","journal-title":"Oncogene"},{"issue":"11","key":"2026070806070559900_bqag063-B32","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/0008-5472.CAN-23-0519","article-title":"Obesogenic high-fat diet and MYC cooperate to promote lactate accumulation and tumor microenvironment remodeling in prostate cancer","volume":"84","author":"Boufaied","year":"2024","journal-title":"Cancer Res"},{"issue":"13","key":"2026070806070559900_bqag063-B33","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.3390\/cancers15133473","article-title":"Lactate as key metabolite in prostate cancer progression: what are the clinical implications?","volume":"15","author":"Chetta","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026070806070559900_bqag063-B34","doi-asserted-by":"crossref","first-page":"e202302146","DOI":"10.26508\/lsa.202302146","article-title":"Proteomic-based stratification of intermediate-risk prostate cancer patients","volume":"7","author":"Zhong","year":"2024","journal-title":"Life Sci Alliance"},{"issue":"4","key":"2026070806070559900_bqag063-B35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/cancers15041051","article-title":"A novel blood proteomic signature for prostate cancer","volume":"15","author":"Muazzam","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026070806070559900_bqag063-B36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J Clin Invest"},{"issue":"13","key":"2026070806070559900_bqag063-B37","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026070806070559900_bqag063-B38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.eururo.2019.08.034","article-title":"Androgen receptor modulation optimized for response-splice variant: a phase 3, randomized trial of galeterone versus enzalutamide in androgen receptor splice variant-7-expressing metastatic castration-resistant prostate cancer","volume":"76","author":"Taplin","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"2026070806070559900_bqag063-B39","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/cancers13061483","article-title":"Cross-resistance to Abiraterone and enzalutamide in castration resistance prostate cancer cellular models is mediated by AR transcriptional reactivation","volume":"13","author":"Simon","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026070806070559900_bqag063-B40","doi-asserted-by":"crossref","first-page":"115089","DOI":"10.1016\/j.celrep.2024.115089","article-title":"Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer","volume":"44","author":"Poluben","year":"2025","journal-title":"Cell Rep"},{"issue":"1","key":"2026070806070559900_bqag063-B41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41467-019-14219-6","article-title":"MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer","volume":"11","author":"Yasumizu","year":"2020","journal-title":"Nat Commun"},{"issue":"11","key":"2026070806070559900_bqag063-B42","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ccell.2022.10.011","article-title":"FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer","volume":"40","author":"Han","year":"2022","journal-title":"Cancer Cell"},{"issue":"12","key":"2026070806070559900_bqag063-B43","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3390\/genes12121900","article-title":"Epithelial\u2013mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics","volume":"12","author":"Chaves","year":"2021","journal-title":"Genes (Basel)"},{"issue":"3","key":"2026070806070559900_bqag063-B44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41419-024-06621-w","article-title":"Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of wnt\/\u03b2-catenin signaling pathway","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"2026070806070559900_bqag063-B45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41420-025-02354-7","article-title":"SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance","volume":"11","author":"Wei","year":"2025","journal-title":"Cell Death Discov"},{"issue":"23","key":"2026070806070559900_bqag063-B46","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2026070806070559900_bqag063-B47","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","article-title":"An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer","volume":"23","author":"Davies","year":"2021","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2026070806070559900_bqag063-B48","doi-asserted-by":"crossref","first-page":"110595","DOI":"10.1016\/j.celrep.2022.110595","article-title":"Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis","volume":"39","author":"Han","year":"2022","journal-title":"Cell Rep"},{"key":"2026070806070559900_bqag063-B49","doi-asserted-by":"crossref","first-page":"1191311","DOI":"10.3389\/fendo.2023.1191311","article-title":"Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution","volume":"14","author":"Imamura","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2026070806070559900_bqag063-B50","doi-asserted-by":"crossref","first-page":"200302","DOI":"10.1098\/rsob.200302","article-title":"Phosphoglycerate kinase: structural aspects and functions, with special emphasis on the enzyme from kinetoplastea","volume":"10","author":"Rojas-Pirela","year":"2020","journal-title":"Open Biol"},{"issue":"3","key":"2026070806070559900_bqag063-B51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.31083\/j.fbl2903092","article-title":"Phosphoglycerate kinase 1: an effective therapeutic target in cancer","volume":"29","author":"Qiu","year":"2024","journal-title":"Front. Biosci. (Landmark Ed)"},{"issue":"11","key":"2026070806070559900_bqag063-B52","first-page":"2280","article-title":"PGK1-mediated cancer progression and drug resistance","volume":"9","author":"He","year":"2019","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2026070806070559900_bqag063-B53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41419-022-04576-4","article-title":"PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4\/ERK signaling pathway and accelerating glycolysis","volume":"13","author":"He","year":"2022","journal-title":"Cell Death Dis"},{"issue":"41","key":"2026070806070559900_bqag063-B54","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.2174\/0929867326666181213092652","article-title":"Unlocking the potential of HK2 in cancer metabolism and therapeutics","volume":"26","author":"Garcia","year":"2019","journal-title":"Curr Med Chem"},{"issue":"1","key":"2026070806070559900_bqag063-B55","doi-asserted-by":"crossref","first-page":"20190003","DOI":"10.1515\/pp-2019-0003","article-title":"Resistance to anoikis in transcoelomic shedding: the role of glycolytic enzymes","volume":"4","author":"Wilson","year":"2019","journal-title":"Pleura Peritoneum"},{"issue":"6","key":"2026070806070559900_bqag063-B56","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2024.04.007","article-title":"Emerging targets in lipid metabolism for cancer therapy","volume":"45","author":"Terry","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"17","key":"2026070806070559900_bqag063-B57","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.3390\/ijms231710037","article-title":"Revisited metabolic control and reprogramming cancers by means of the warburg effect in tumor cells","volume":"23","author":"Fukushi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2026070806070559900_bqag063-B58","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.bulcan.2022.07.004","article-title":"Roles and mechanisms of phosphoglycerate kinase 1 in cancer","volume":"109","author":"Chen","year":"2022","journal-title":"Bull Cancer"},{"key":"2026070806070559900_bqag063-B59","doi-asserted-by":"crossref","first-page":"682461","DOI":"10.3389\/fonc.2021.682461","article-title":"PGK1 is a key target for anti-glycolytic therapy of ovarian cancer: based on the comprehensive analysis of glycolysis-related genes","volume":"11","author":"Gou","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"2026070806070559900_bqag063-B60","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cells9102308","article-title":"Cancer metabolism: phenotype, signaling and therapeutic targets","volume":"9","author":"Park","year":"2020","journal-title":"Cells"},{"issue":"1","key":"2026070806070559900_bqag063-B61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41420-021-00520-1","article-title":"Metabolic protein phosphoglycerate kinase 1 confers lung cancer migration by directly binding HIV tat specific factor 1","volume":"7","author":"Chang","year":"2021","journal-title":"Cell Death Discov"},{"issue":"1","key":"2026070806070559900_bqag063-B62","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1186\/s12885-024-12792-8","article-title":"Acetylation of PGK1 at lysine 323 promotes glycolysis, cell proliferation, and metastasis in luminal A breast cancer cells","volume":"24","author":"Gao","year":"2024","journal-title":"BMC Cancer"},{"issue":"5","key":"2026070806070559900_bqag063-B63","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.molcel.2017.01.027","article-title":"Phosphoglycerate kinase 1 phosphorylates Beclin1 to induce autophagy","volume":"65","author":"Qian","year":"2017","journal-title":"Mol Cell"},{"issue":"7","key":"2026070806070559900_bqag063-B64","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1080\/15548627.2017.1313945","article-title":"Protein kinase activity of the glycolytic enzyme PGK1 regulates autophagy to promote tumorigenesis","volume":"13","author":"Qian","year":"2017","journal-title":"Autophagy"},{"issue":"5","key":"2026070806070559900_bqag063-B65","doi-asserted-by":"crossref","first-page":"e70028","DOI":"10.1111\/1759-7714.70028","article-title":"ACT001 suppresses the malignant progression of small-cell lung cancer by inhibiting lactate production and promoting anti-tumor immunity","volume":"16","author":"Ding","year":"2025","journal-title":"Thorac Cancer"},{"issue":"36","key":"2026070806070559900_bqag063-B66","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1038\/onc.2014.25","article-title":"Targeting autophagy overcomes enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model","volume":"33","author":"Nguyen","year":"2014","journal-title":"Oncogene"},{"issue":"5","key":"2026070806070559900_bqag063-B67","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.eururo.2018.06.020","article-title":"Patient-derived models of Abiraterone- and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy","volume":"74","author":"Lawrence","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"2026070806070559900_bqag063-B68","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13046-025-03356-0","article-title":"Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer","volume":"44","author":"N\u00f8rgaard","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2026070806070559900_bqag063-B69","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41467-018-06067-7","article-title":"Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"issue":"31","key":"2026070806070559900_bqag063-B70","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1200\/JCO.20.00348","article-title":"Exploring spatial-temporal changes in 18F-sodium fluoride PET\/CT and circulating tumor cells in metastatic castration-resistant prostate cancer treated with enzalutamide","volume":"38","author":"Kyriakopoulos","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026070806070559900_bqag063-B71","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.omtn.2023.02.022","article-title":"Enzalutamide-induced signatures revealed by epigenetic plasticity using single-cell multi-omics sequencing in prostate cancer","volume":"31","author":"Fan","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"issue":"19","key":"2026070806070559900_bqag063-B72","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.3390\/cancers17193187","article-title":"Dynamic reprogramming of immune-related signaling during progression to enzalutamide resistance in prostate cancer","volume":"17","author":"Xu","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"44","key":"2026070806070559900_bqag063-B73","doi-asserted-by":"crossref","first-page":"e10602","DOI":"10.1002\/advs.202510602","article-title":"Enzalutamide-resistant STEAP4(+) MyoCAF secrete phosphatidylcholine to foster progression by activating stemness in hormone-sensitive prostate cancer","volume":"12","author":"Wang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2026070806070559900_bqag063-B74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.gendis.2023.01.026","article-title":"The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy","volume":"11","author":"Alam","year":"2024","journal-title":"Genes Dis"},{"issue":"8","key":"2026070806070559900_bqag063-B75","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41388-021-02155-z","article-title":"Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer","volume":"41","author":"Xu","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"2026070806070559900_bqag063-B76","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","article-title":"Mitochondrial metabolism and cancer therapeutic innovation","volume":"10","author":"Du","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2026070806070559900_bqag063-B77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol Cancer"},{"issue":"6487","key":"2026070806070559900_bqag063-B78","doi-asserted-by":"crossref","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"issue":"9","key":"2026070806070559900_bqag063-B79","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.31557\/APJCP.2025.26.9.3157","article-title":"Fueling prostate cancer: the central role of glutamine\/glutamate metabolic reprogramming","volume":"26","author":"Alhallaq","year":"2025","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"2026070806070559900_bqag063-B80","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41419-024-06893-2","article-title":"Targeting valine catabolism to inhibit metabolic reprogramming in prostate cancer","volume":"15","author":"Bidgood","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"2026070806070559900_bqag063-B81","doi-asserted-by":"crossref","first-page":"24","DOI":"10.54097\/zta8d431","article-title":"Progress in PGK1 in prostate cancer","volume":"8","author":"Lu","year":"2024","journal-title":"Int J Biol Life Sci"},{"issue":"4","key":"2026070806070559900_bqag063-B82","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/pros.24654","article-title":"Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer","volume":"84","author":"Moon","year":"2024","journal-title":"Prostate"},{"issue":"26","key":"2026070806070559900_bqag063-B83","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41388-024-03059-4","article-title":"Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer","volume":"43","author":"Beier","year":"2024","journal-title":"Oncogene"},{"issue":"1","key":"2026070806070559900_bqag063-B84","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13046-025-03430-7","article-title":"Targeting glutamine metabolism as a potential target for cancer treatment","volume":"44","author":"Zou","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2026070806070559900_bqag063-B85","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41467-023-36651-5","article-title":"mcPGK1-dependent mitochondrial import of PGK1 promotes metabolic reprogramming and self-renewal of liver TICs","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"issue":"878","key":"2026070806070559900_bqag063-B86","doi-asserted-by":"crossref","first-page":"eadi5174","DOI":"10.1126\/scisignal.adi5174","article-title":"The kinase PLK1 promotes Hedgehog signaling-dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer","volume":"18","author":"Zhang","year":"2025","journal-title":"Sci Signal"},{"issue":"1","key":"2026070806070559900_bqag063-B87","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12967-025-06457-8","article-title":"An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer","volume":"23","author":"Zhuang","year":"2025","journal-title":"J Transl Med"},{"issue":"1","key":"2026070806070559900_bqag063-B88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.17161\/sjm.v1i1.23189","article-title":"Plk1, a promising THERAPEUTIC target for prostate cancer treatment","volume":"1","author":"Peng","year":"2024","journal-title":"Serican J Med"},{"issue":"1","key":"2026070806070559900_bqag063-B89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13046-022-02331-3","article-title":"PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2","volume":"41","author":"Zhao","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"13","key":"2026070806070559900_bqag063-B90","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.7150\/jca.86940","article-title":"circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis","volume":"14","author":"Zhou","year":"2023","journal-title":"J Cancer"},{"issue":"22","key":"2026070806070559900_bqag063-B91","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/0008-5472.CAN-23-0308","article-title":"Targeting the metabolic enzyme PGAM2 overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting BCL2 signaling","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"2026070806070559900_bqag063-B92","doi-asserted-by":"crossref","first-page":"101466","DOI":"10.1016\/j.molmet.2022.101466","article-title":"Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC)","volume":"59","author":"Xu","year":"2022","journal-title":"Mol Metab"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqag063\/68377561\/bqag063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/7\/bqag063\/68377561\/bqag063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/7\/bqag063\/68377561\/bqag063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:07:23Z","timestamp":1783505243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqag063\/8691859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":92,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqag063","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,24]]},"article-number":"bqag063"}}